Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results? * Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC: * Receive Cadonilimab combined with SRT for brain lesions. * Visit the hospital regularly once every 12 weeks for checkups and tests

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Rongrong ZhouUpdated: Nov 25, 2024Locations: 1
Eligibility criteria

18 years old ≤ 75 years old; Both male and female; [+13]

Experienced grade 3-4 intracranial toxicity (pituitary or central nervous system... [+17]

Status: Recruiting

Hypofractionated Radiotherapy for Thymic Epithelial Tumors

The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are: * Does Hypofractionated radiotherapy provide better results? * Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery. Participants will: * Receive hypofractionated radiotherapy or conventional radiotherapy * Visit the hospital regularly once every 12 weeks for checkups and tests

Participants needed: 100
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Rongrong ZhouUpdated: Nov 18, 2024Locations: 1
Eligibility criteria

Patients must provide written informed consent. [+8]

patients with prior thoracic radiotherapy; [+5]